Literature DB >> 24848756

Luseogliflozin: first global approval.

Anthony Markham1, Shelley Elkinson.   

Abstract

Luseogliflozin [Lusefi(®) (Japan)] is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). The drug has received its first global approval for this indication in Japan, either as monotherapy or in combination with other antihyperglycaemic agents. This article summarises the milestones in the development of luseogliflozin leading to this first approval for the treatment of T2DM.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24848756     DOI： 10.1007/s40265-014-0230-8

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

Review 1.  Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A DeFronzo
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 2.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

3.  Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.

Authors:  Yutaka Seino; Takashi Sasaki; Atsushi Fukatsu; Michito Ubukata; Soichi Sakai; Yoshishige Samukawa
Journal:  Curr Med Res Opin       Date:  2014-04-15       Impact factor: 2.580

4.  TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.

Authors:  K Yamamoto; S Uchida; K Kitano; N Fukuhara; L Okumura-Kitajima; E Gunji; A Kozakai; H Tomoike; N Kojima; J Asami; H Toyoda; M Arai; T Takahashi; K Takahashi
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.

Authors:  Hiroyuki Kakinuma; Takahiro Oi; Yuko Hashimoto-Tsuchiya; Masayuki Arai; Yasunori Kawakita; Yoshiki Fukasawa; Izumi Iida; Naoko Hagima; Hiroyuki Takeuchi; Yukihiro Chino; Jun Asami; Lisa Okumura-Kitajima; Fusayo Io; Daisuke Yamamoto; Noriyuki Miyata; Teisuke Takahashi; Saeko Uchida; Koji Yamamoto
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

6.  Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

Authors:  Yutaka Seino; Takashi Sasaki; Atsushi Fukatsu; Michito Ubukata; Soichi Sakai; Yoshishige Samukawa
Journal:  Curr Med Res Opin       Date:  2014-04-29       Impact factor: 2.580

7.  Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

Authors:  Takashi Sasaki; Yutaka Seino; Atsushi Fukatsu; Soichi Sakai; Yoshishige Samukawa
Journal:  Adv Ther       Date:  2014-02-18       Impact factor: 3.845
  7 in total
  31 in total

Review 1.  The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation.

Authors:  Li Di; Amanda Balesano; Samantha Jordan; Sophia M Shi
Journal:  AAPS J       Date:  2021-01-07       Impact factor: 4.009

Review 2.  Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 3.  Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 4.  The renal effects of SGLT2 inhibitors and a mini-review of the literature.

Authors:  Vasileios Andrianesis; Spyridoula Glykofridi; John Doupis
Journal:  Ther Adv Endocrinol Metab       Date:  2016-11-11       Impact factor: 3.565

Review 5.  Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.

Authors:  Linda A Gallo; Ernest M Wright; Volker Vallon
Journal:  Diab Vasc Dis Res       Date:  2015-01-23       Impact factor: 3.291

Review 6.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

7.  Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology.

Authors:  Anzhu Wang; Zhendong Li; Sun Zhuo; Feng Gao; Hongwei Zhang; Zhibo Zhang; Gaocan Ren; Xiaochang Ma
Journal:  Front Cardiovasc Med       Date:  2022-05-23

Review 8.  Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

9.  Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.

Authors:  Elza Muscelli; Brenno Astiarraga; Elisabetta Barsotti; Andrea Mari; Freimut Schliess; Leszek Nosek; Tim Heise; Uli C Broedl; Hans-Juergen Woerle; Ele Ferrannini
Journal:  Diabetologia       Date:  2015-12-24       Impact factor: 10.122

10.  Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.

Authors:  Takashi Sasaki; Yutaka Seino; Atsushi Fukatsu; Michito Ubukata; Soichi Sakai; Yoshishige Samukawa
Journal:  Adv Ther       Date:  2015-05-15       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.